Canadian Cancer Trials Group Bulletins

Trial Management Group

Trials Closed to Accrual

Canadian Cancer Trials Group MAP.3 -- A Phase III Randomized Study of Exemestane vs Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer -- was closed 23 March 2010 after reaching its target accrual.

This is a momentous day for our prevention program! Thank you to everyone who has committed so much time and effort to this project. It would not be complete without extending an extra special thank you to Dianne Johnston who dedicated close to a decade of her life working on our Prevention Initiative and helping to build and motivate a fabulous network of investigators and staff who in turn were able to make this day a possibility!

We sincerely appreciate the hard work and dedication of everyone who has contributed to this important study.


Canadian Cancer Trials Group CE.5/EORTC 22033-26033 -- Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study -- is now closed to further registrations of new patients effective 26 March 2010. The accrual target was met.


Canadian Cancer Trials Group MA.29 -- A Feasibility Study of Pre-Operative Sunitinib (SU11248) with Multiple Pharmacodynamic Endpoints in Patients with T1c - T3 Operable Carcinoma of the Breast -- was permanently closed 15 March 2010. The trial was closed due to two recent studies which demonstrated the lack of activity of sunitinib in breast cancer.